



STFV

CERTIFICATE OF MAILING
UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313 on

11 July 2005
HUESCHEN AND SAGE

Michael M. Cus
Dated: 11 July 2005

PF 114 CIP

Applicant : Jean DEREGNAUCOURT and Richard GROSSE
Serial No. : 10/805,940
Filed : March 22, 2004
Title : USE OF THE (1S,2R) ENANTIOMER OF MILNACIPRAN
FOR THE PREPARATION OF A DRUG
Art Unit : 1616
Examiner : Frank I. CHOI, Esq.

Honorable Commissioner for Patents
PO Box 1450
Alexandria, VA 22313

COMMUNICATION COVERING TRANSMITTAL OF INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §§ 1.97 AND 1.98

Sir:

Herewith, in accord with the foregoing regulations, please find an Information Disclosure Statement which, it is respectfully submitted, should materially advance and accelerate the prosecution of the above-identified application. It is respectfully requested that the information be expressly considered during the prosecution of

07/14/2005 SFELEKE1 00000003 10805940

01 FC:1806

180.00 OP

this application and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

As will be noted, this Information Disclosure Statement calls a number of prior art references, which might be considered relevant, to the attention of the Examiner. The fact that these are in fact "Prior Art" is, however, not admitted.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR § 1.98 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,
THE FIRM OF HUESCHEN AND SAGE

By: 
G. PATRICK SAGE


Dated: July 11, 2005
Customer No.: 25,666
Seventh Floor, Kalamazoo Building
107 West Michigan Avenue
Kalamazoo, MI 49007
(269) 382-0030

Enclosure: Form PTO-1449 and Accompanying References (including Certified Translation of non-English Reference), Check No. 73674 for IDS Fee, and Postal Card Receipt.

* * * * *

THE COMMISSIONER IS HEREBY AUTHORIZED TO CHARGE ANY FURTHER OR ADDITIONAL FEES WHICH MAY BE REQUIRED (DUE TO OMISSION, DEFICIENCY, OR OTHERWISE), OR TO CREDIT ANY OVERPAYMENT, TO DEPOSIT ACCOUNT NO. 08,3220.

PTO-1449 LIST OF PRIOR ART CITED BY APPLICANT SHEET 1 OF 1	ATTY. DOCKET NO. PF 114 CIP	SERIAL NO. 10/805,940
	APPLICANT Jean DEREGNAUCOURT and Richard GROSSE	
	FILING DATE March 22, 2004	GROUP 1616



U.S. PATENT DOCUMENTS

Examiner Initial	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
					YES	NO

OTHER PRIOR ART

	ARTIGAS, "Selective Serotonin/Noradrenaline Reuptake Inhibitors", <i>CNS Drugs</i> , 1995, 4, 79-89.
	PRESKORN, et al., "Other Antidepressants", <i>Antidepressants: Past, Present and Future</i> , 2004, 264-311.
	PRESKORN, "Milnacipran: A Dual Norepinephrine and Serotonin Reuptake Pump Inhibitor", <i>Journal of Psychiatric Practice</i> , 2004, 10, 119-126.
	YOSHIDA, et al., "Elevation of blood pressure induced by high-dose milnacipran", <i>Hum. Psychopharmacol. Clin. Exp.</i> , 2002, 17, 431.
	SCHORDERET, "Effets sur le système cardiovasculaire", <i>PHARMACOLOGIE DES CONCEPTS FONDAMENTAUX AUX APPLICATIONS THÉRAPEUTIQUES</i> , 1992, Chapter 25, pages 363-364.
	ENER, et al., "Serotonin Syndrome and Other Serotonergic Disorders", <i>Pain Medicine</i> , 2003, 4, 63-74.
	KOLECKI, "Isolated Venlafaxine-Induced Serotonin Syndrome", <i>J. Emerg. Med.</i> , 1997, 15, 491-493.
	HANSEN, et al., "Long-term antidepressive medication – an increased anesthetic risk?", <i>Der Anaesthesist</i> , 1990, 39, 205-210 (<i>Surgical Medline Extract</i>).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO-1449 LIST OF PRIOR ART CITED BY APPLICANT SHEET <u>2</u> OF <u>2</u>	ATTY. DOCKET NO. PF 114 CIP	SERIAL NO. 10/805,940
	APPLICANT Jean DEREGNAUCOURT and Richard GROSSE	
	FILING DATE March 22, 2004	GROUP 1616

OTHER PRIOR ART

	THASE, "Effects of Venlafaxine on Blood Pressure: A Meta-Analysis of Original Data from 3744 Patients", <i>J. Clin. Psychiatry</i> , 1998 , 59, 502-508.		
	PARTRIDGE, et al., "A Depressed Myocardium", <i>Clinical Toxicology</i> , 2000 , 38, 453-455.		
	JORDAN, et al., "Influence of sibutramine on blood pressure: evidence from placebo-controlled trials", <i>Int. J. Obes. Relat. Metab. Disord.</i> , 2005 , 29, 509-516 (<i>Medline Extract</i>).		
	BIRKENFELD, et al., "Paradoxical effect of sibutramine of autonomic cardiovascular regulation", <i>Circulation</i> , 2002 , 106, 2459-2465 (<i>Medline Extract</i>).		
	SRAMEK, et al., "Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial", <i>J. Hum. Hypertens.</i> , 2002 , 16, 13-19 (<i>Medline Extract</i>).		
	SZABADI, et al., "The human pharmacology of reboxetine", <i>Hum. Psychopharmacol.</i> , 1998 , Suppl. 1, S3-S12 (<i>Excerpta Medica Extract</i>).		
	MIDDLETON, et al., "Evidence that imipramine-induced postural hypotension may be centrally mediated", <i>Hum. Psychopharmacol.</i> , 1998 , 3, 181-190 (<i>Excerpta Medica Extract</i>).		
	ROBINSON, "Antidepressant Psychopharmacology: Current Limitations and Future Directions", <i>Primary Psychiatry</i> , 2003 , 10, 43-49.		
<table border="1"> <tr> <td>EXAMINER</td> <td>DATE CONSIDERED</td> </tr> </table>		EXAMINER	DATE CONSIDERED
EXAMINER	DATE CONSIDERED		
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			